All News - ALZFORUM
WEBSep 27, 2024 · CSF Proteins Spot Alzheimer’s Mutation Carriers Decades Before Symptoms. Add To My AlzForum. 27 Sep 2024. A CSF proteomics study in ADAD mutation carriers identified 137 potential markers. They span the AD continuum. For 12 of them, their concentrations change prior to those of classic AD biomarkers. New Alzheimer’s Gene? Cytochrome P450 ...
ALZFORUM | NETWORKING FOR A CURE
WEBOct 1, 2024 · Everywhere, according to a new snRNA-Seq study of more than 400 postmortem brains. The authors identified one microglial subtype that promotes plaques, another that promotes tangles, and an astrocyte subtype that contributes to cognitive decline. Intriguingly, in brains with plaques but few …
How Will Alzheimer’s Trials, Treatment Change in 2023 and Beyond?
WEBTools. 07 Oct 2022. When Eisai and Biogen announced positive top-line results for their anti-amyloid antibody lecanemab, the trial became the first successful, completed Phase 3 Alzheimer's drug study in the Western world in more than 20 years. If lecanemab earns traditional approval from the U.S. Food and Drug Administration based on these ...
CSF Proteins Spot Alzheimer’s Mutation Carriers Decades Before …
WEBTools. 27 Sep 2024. Long before carriers of autosomal-dominant AD mutations notice the first hints of memory loss, changes in their brains are well underway at the protein level. In a study published September 26 in Cell, scientists led by Carlos Cruchaga at Washington University in St. Louis provide further support for this concept.
2023—A Bumper Year for the Treatment and Science of Alzheimer's
WEBDec 26, 2023 · Lecanemab (bottom panel) reduced plaque load over the same period. [Courtesy of Eisai.] Alzforum's raison d'etre, it could be said, is to facilitate the search for treatments for Alzheimer's and related diseases. The year 2023 was a good year for this, as the U.S. FDA approved several drugs, compared to none in 2022.
New Alzheimer’s Diagnostic Criteria Remain ‘Research Only’
WEBTools. 28 Nov 2023. The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more accurately reflecting the underlying biology of the disease, they also have sparked criticism for advancing toward clinical use ...
Revised Again: Alzheimer's Diagnostic Criteria Get Another …
WEBSep 16, 2022 · 17 Aug 2023. Diagnostic criteria for Alzheimer’s disease were revised only five years ago, but the field has learned a lot since then. At the Alzheimer’s Association International Conference, held last month in Amsterdam, Clifford Jack of the Mayo Clinic in Rochester, Minnesota, proposed updates to the current “ATN” system.
Polygenic Scores Point to Microglia, Astrocytes in Alzheimer's ...
WEBDec 15, 2023 · What Each Cell Does. Statistical modeling hints at causal relationships between astrocyte- and microglia-specific polygenic risk (ADPRS) and Alzheimer's endophenotypes. Black arrows indicate phenotype-phenotype associations; red arrows indicate genotype-phenotype associations. DP=diffuse plaque, NP=neuritic plaque, NFT=neurofibrillary tangle.
Massive GWAS Meta-Analysis Digs Up Trove of Alzheimer’s Genes
WEBFeb 25, 2021 · A meta-analysis in 2013 pulled together 17,000 cases and turned up 19 risk loci, 11 of them new (Oct 2013 news). Geneticists at the International Genomics of Alzheimer’s Project analyzed more than 35,000 cases to find five new loci (Mar 2019 news). A separate effort went broader by including UK Biobank samples from people with family ...
FDA Will Regulate Diagnostic Tests. Yes, Those for Alzheimer’s, Too.
WEB10 May 2024. For decades, the U.S. Food and Drug Administration has taken a light touch to regulating diagnostic tests that use body fluids or tissues. Such assays, very much including cerebrospinal fluid and blood tests for Alzheimer’s disease, were able to be marketed without providing proof of accuracy in the intended population. Now, the ...